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Abstract 
Purpose: To determine the compliance of patent medicine vendors (PMVs) in rural areas of Lagos 
State, Nigeria with set guidelines to regulate their practice and its implications for malaria control. 
Methods: A baseline cross-sectional study was conducted as part of an intervention study in two rural 
local government areas (LGAs) of Lagos State Nigeria. One hundred and eighty PMVs were randomly 
selected and interviewed using structured questionnaire. In addition, an observational checklist was 
used to monitor the drug shops for compliance with regulatory guidelines. Indicators of compliance used 
include proportion of PMVs with valid practicing license and proportion of shops with duly registered 
anti-malaria drugs.  
Results: Most 148 (82.2 %) of the respondents were shop owners with 170 (94.4 %) aged ≥ 21 years 
(the minimum age required by law) and a mean of 30.9 ± 8 years (range 16 - 67years). Only two (1.1 %) 
PMVs had a valid annual practicing licence and only three (1.7 %) of the drug shops had specified sign-
posts. The shops stocked various kinds of anti-malaria drugs including those that are no longer 
recommended. All the sampled drugs were duly registered with NAFDAC and within expiry dates.  
Conclusion: There was poor compliance with regulatory guidelines. A strict enforcement of the 
guidelines by the regulatory agency is recommended to ensure that only licensed persons sell 
appropriate anti-malaria drugs.  
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Patent Medicine Vendors (PMVs) are important 
informal community-based providers of health 
care [1-4]. Many countries, recognizing their role 
and contribution to ensuring equitable access by 
the population to essential drugs, permit them to 
sell certain over-the-counter (OTC) drugs, 
including anti-malaria drugs and other drugs for 
treatment of common ailments [5-7].  
 
The activities of PMVs are usually regulated by 
agencies of government [6,7]. In Nigeria, 
Pharmacists Council of Nigeria (PCN) regulates 
PMVs’ activities as established in Pharmacy 
Council of Nigeria Decree 91 of 1992 [8]. PCN 
specifies eligibility criteria for operating as a 
PMV, stipulates licensing requirements, and 
gives guidelines for operators to follow. While 
PCN regulates the activities of PMVs, drug 
registration and regulation are within the purview 
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of National Agency for Food and Drug 
Administration and Control (NAFDAC) [5].  
 
Malaria remains a leading cause of morbidity and 
mortality in Nigeria as in other sub-Saharan 
Africa countries [9]. According to the new 
antimalarial treatment policy, trained PMVs are 
categorized in level 1 of malaria management 
[10]. At this level, a health care provider is 
expected to diagnose malaria symptomatically 
and administer artemisinin-based combination 
therapy (ACTs) for uncomplicated cases or give 
pre-referral treatment and promptly refer patients 
with severe febrile illness. PMVs will continue to 
play a major role in malaria treatment especially 
those in the rural areas where the burden of 
malaria is higher [11,12]. Not much is known 
about PMVs operating in the rural areas of Lagos 
and their level of compliance with PCN and 






Lagos State is one of the 36 states of the Federal 
Republic of Nigeria. It is located in the 
southwestern zone of Nigeria and is the 
commercial nerve centre of the country. It is 
divided into 20 Local Government Areas (LGAs); 
16 are classified as urban and four as rural. The 
rural LGAs are Ikorodu, Epe, Ibeju-Lekki and 
Badagry. The study was carried out in Ikorodu 
and Ibeju-lekki. 
 
The Ikorodu branch of the Lagos State Medicine 
Dealers Association (LSMDA) had 482 registered 
PMVs in its four zones in the LGA and they were 
distributed thus: Ikorodu South (82), Ikorodu 
Central (75), Odogunyan (184) and Igbogbo 
(141). The Ibeju-Lekki branch of LSMDA had 157 
registered PMVs.  
 
There were two independent umbrella 
associations for PMVs in Lagos state: Lagos 
State Medicine Dealers’ Association (LSMDA) 
and National Association of Patent and 
Proprietary Medicine Dealers (NAPPMED). We 
first established contact with LSMDA; it was 
much later while pre-testing the data collection 
instruments that the parallel group was 
discovered. We decided to limit the study to 
LSMDA to avoid the complexity of involving the 
two bodies. Lagos State Medicine Dealers’ 
Association (LSMDA) had a branch in each LGA 
and for ease of administration, big LGA branches 
were further divided into zones. The state and 
the LG branches all had executive committees 
running the association.  
 
Study design and study population 
 
This was a cross-sectional study to determine 
the compliance with relevant regulatory 
guidelines by PMVs operating in rural LGAs of 
Lagos state. The study population comprised 
LSMDA-registered PMVs operating in Ikorodu 
(Odogunyan zone) and in Ibeju-Lekki LGAs of 
Lagos state. Only PMVs who had their patent 
medicines shops registered with the LGA branch 
of LSMDA were included in the study. Where the 
shop owner was not the one actively involved in 
operating a selected shop, the person in charge, 
either an apprentice or a sales attendant who 
usually sold drugs to clients, was interviewed.  
 
Sample size estimation 
 
The minimum sample size for the main study 
(intervention) was estimated using the formula 
for comparison of two proportions [13] and a 




The proposed intervention study was designed to 
take place in two rural LGAs (one to serve as 
intervention and the other as control LGA). Using 
simple random sampling method by balloting, 
Ikorodu and Ibeju-Lekki LGAs were selected. In 
Ikorodu, only Odogunyan zone (the largest zone) 
was involved in the study. The methodological 
and logistic challenge of involving all the zones 
informed the purposive selection of Odogunyan 
zone where it was most certain that the required 
number of PMVs for Ikorodu would be obtained. 
Simple random sampling method was used to 




Ethical approval for the study was obtained from 
the Research and Ethics Committee of the Lagos 
University Teaching Hospital. Meetings were 
held with the executive bodies of LSMDA at the 
state and LGA levels. We also attended the 
monthly meetings of the two LGAs and explained 
the purpose of the study to members. Informed 
consent was obtained from the respondents and 
they were further assured of the confidentiality of 
the information they would provide.  
 
Data collection and analysis 
 
Data were collected between July and 
September 2009. Executive members of LSMDA 
in each LGA helped to locate the selected shops 
and assure respondents of the association’s 
approval. One of the authors and two trained 
research assistants administered the pretested 
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structured questionnaire and observational 
checklist to respondents and their shops. The 
questionnaire elicited inter alia information on the 
socio-demographic characteristics of the PMVs 
and their work history. The observational 
checklist was used to check the shop premises, 
the types of antimalaria drugs in the shops, and 
the expiry date and registration status of the 
drugs. All the antimalaria drugs (AMDs) in stock 
for sale were identified, and one of each type of 
the drugs shown was arbitrarily selected by the 
interviewer and checked for NAFDAC number 
and expiry date. The Epi Info 2002 (Windows 
version 3.5.1) was used for data entry, cleaning, 
and analysis. Chi-square test (with Yates 
correction) and Fisher exact test were used to 
determine associations between qualitative 
variables. A p-value of < 0.05 was considered 




Table 1 shows that most 148 (82.2%) of the 
respondents were shop owners. Respondents’ 
ages ranged from 16 to 67years, with a mean 
age of 30.9 ± 8 years, and 94.4% were ≥ 21years 
(21 years is the minimum age required by PCN 
to be licensed to operate as a PMV [8]). The 
highest level of education attained by the PMVs 
was secondary education 144 (80%). There were 
more females 95 (52.8%) than males 85 (47.2%) 
and most are married 107 (59.4%). Most of the 
PMVs were of Igbo 85 (47.2%) ethnic extraction 
and the dominant religion was Christianity 156 
(86.7%). Some significant differences exist 
between the two LGAs. 
 
Training and work history 
 
About a third 57 (31.7%) of the respondents had 
health-related training background and majority 
of them were trained as auxiliary nurses. The 
PMVs had been in practice for a mean duration 
of 5.4 ± 4.7 years. About two-third 114 (63.3 %) 
of the PMVs mentioned attending a continuing 
education programme (CEP) in the previous 24 
months, less than a half 75 (41.7 %) attended 
one specifically on malaria. Significantly more 
PMVs in Ikorodu attended CEPs than their 
counterparts in Ibeju-Lekki. Only 10 (6.3 %) of 
shop owners claimed having a practising licence 
and for most of them 163 (90.6%), operating their 
shop was their only job (Table 2).  
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Table 3: Findings from observation of patent medicine shops 
 




Total χ2 P-value 


















Wording in business 
name 

















Nature of shop 
Drug shop only 




























































*Fisher exact p-value 
Oyeyemi et al 
Trop J Pharm Res, January 2014; 13(1): 166  
 
Table 4: Types of antimalarial drugs found in the observed patent medicine shops 
 












ACTs 39 (43.3) 67 (74.4) 106 (58.9) 16.73 <0.001 
Artemisinin 
monotherapies  
66 (73.3) 70 (77.8) 136 (75.6) 0.27 0.603 
Chloroquine 80 (88.9) 87 (96.7) 167 (92.8) 2.98 0.084 
Amodiaquine 17 (18.9) 10 (11.1)   27 (15.0) 1.57 0.210 
Sulphadoxine-
pyrimethamine 
81 (90.0) 77 (85.6) 158 (87.8) 0.47 0.495 
Quinine 4 (4.4) 7 (7.8)   11 (6.1) 0.39 0.534 
Pyrimethamine 3 (3.3) 10 (11.1)   13 (7.2) 2.98 0.084 
Halofantrine 2 (2.2) 10 (11.1)   12 (6.7) 4.38 0.036 
Others 0 (0.0) 3 (3.3)    3 (1.7)  0.246* 
* Fisher exact p-value 
 
Observational findings on drug shops 
 
Only seven (3.9 %) shops had sign-post 
announcing their premises and only three out of 
the seven contained the required wordings. Of 
all, only six (3.3 %) of the stores had the shop 
owners’ annual practising license conspicuously 
displayed or presented on request. Majority of 
the shops surveyed functioned as both a drug 
shop and a provision store (Table 3). All the 
antimalarials examined had NAFDAC number 
and none had expired.  
 
Different types of antimalarials were stocked in 
both areas (Table 4). “Others” were herbal 
products called “M & T” capsule labeled as “…for 
malaria treatment” and carried NAFDAC number. 
In only one shop was an injectable antimalarial 




This study describes the people operating as 
PMVs in rural Lagos and reports their status as 
regards compliance with regulatory bodies’ (PCN 
and NAFDAC) guidelines. Other studies in 
Nigeria found a lower proportion of respondents 
as shop owners [10, 14]. This may be attributable 
to the fact that running the shop was the only 
source of income for most of the PMVs in this 
study as opposed to the cited studies where 
respondents had other sources of income. The 
finding of apprentices or sales attendants selling 
antimalarials calls for concern. They may not 
have adequate knowledge of malaria treatment 
compared to the shop owners and may not be 
able to sell appropriate drugs in the correct 
doses to their clients, a practice that may result 
in poor treatment with consequences such as 
recrudescence, drug resistance, progression 
from uncomplicated to severe malaria and 
ultimately avoidable death. This finding also 
shows that any capacity building programme for 
PMVs may be more effective if apprentices and 
sales attendants are involved since they interface 
with clients in a number of shops. The finding of 
respondents younger than 21 years was due to 
the participation of apprentices and sales 
attendants. When both were excluded from the 
data, the age range was 22 - 67 years. This 
complies with PCN’s minimum requirement of 
21years for a PMV to be licensed [8]. Maturity is 
essential in the business as a PMV is not just a 
seller; s/he needs to counsel clients and often 
has to make treatment decisions for them, a task 
that can only be successfully performed by an 
adult.  
 
About a third of the PMVs in the study had 
previous health-related training. This proportion 
is higher than that found in other studies in 
Nigeria [14-16], but much lower than what was  
reported in studies in Tanzania where 93-97% of  
PMVs had formal health training [6,17]. This 
disparity is not unexpected as it is mandatory for 
PMVs in Tanzania to have formal health training 
before they can be licensed to practise [6], while 
in Nigeria the educational requirement is just 
being able to read and write in English language 
[8]. Basic health training would no doubt expose 
PMVs to rudiments of malariology and the 
understanding of other common ailments 
including the basic pharmacology of drugs meant 
to treat those ailments, thus enhancing 
appropriate treatment.  
 
For majority of the vendors, operating their drug 
shops was their only business. The study in 
Kaduna, Nigeria also reported a high figure of 
about 80% operating their shops as their sole 
business [14]. Organizing a programme that 
would enhance the malarial treatment practice 
and increase patronage and sales by PMVs 
would probably have a great appeal since their 
shops were the only business concern most of 
them had. At the same time since most of them 
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were shop owners, it might be difficult to call 
them out for long sessions of training. This 
should be factored into any training that would be 
organized for them; multiple short sessions 
rather than long sessions would probably yield 
better result. [18,19]   
 
About two-thirds of the PMVs attended some 
form of continuing education programme (CEP) 
in the previous two years - a prerequisite for 
licence renewal by the PCN [8]. It is the duty of 
the PCN to organize such CEPs for licensed 
PMVs [8], but since majority of the PMVs were 
unlicensed, PCN could not have been the 
organizer of the attended CEPs. This implies that 
the largely unlicensed PMVs had not been 
officially exposed by the regulatory body to any 
formal lecture/training to improve their practice in 
the last two years prior to data collection, despite 
new policies and developments in the 
management of some of the common ailments 
for which they are consulted by the community. 
For malaria, less than half of the PMVs had 
attended at least one CEP. Some of the 
programmes attended, especially those 
organized by pharmaceutical companies, may 
just be drug presentations where adequate 
knowledge about the disease may not be 
passed. This underscores the importance of 
government taking the lead in organizing CEPs 
for both licensed and unlicensed PMVs. If the 
PCN has failed in stopping unlicensed PMVs 
from operating, it will be disastrous to pretend 
they do not exist and exclude them from 
orientation and education programmes that can 
enhance their contribution to appropriate malaria 
treatment. 
  
There was worrisome violation of guidelines set 
by the PCN for operating as a PMV and for 
owning a drug shop. An insignificant number had 
a sign-post and out of those that had, only a few 
carried the prescribed wordings. Without a 
signpost it would be difficult for the PCN and 
other legal and relevant agencies that may want 
to monitor their activities to identify their business 
premises. Almost all the vendors were operating 
without practising license from the PCN. Many 
claimed they had applied and were in the 
process of being licensed. As explained by 
officers of the association in a preliminary 
discussion with them, the licensing process is 
long and may take several months or years. 
There was a long period when issuance of 
licence to PMVs was suspended because of 
conflict among the stakeholders in the regulation 
of their practice [20]. This could partly explain 
why most of them did not have licence. 
Nonetheless, the fact that many of them had 
been in practice for many years without licence 
(not even expired one) reflects a weak 
enforcement by the PCN. A similar study among 
PMVs done in Kaduna, Nigeria reported a much 
higher figure of 56% displaying their licenses, 
though the status of the licences was not 
mentioned [14]. The PMVs in the Kaduna study 
belonged to NAPPMED (we worked with LSMDA 
members), a parallel body of PMVs. Could there 
be a fundamental difference in the way both 
bodies comply with rules? Unlicensed 
businesses are more difficult to regulate and this 
creates room for malpractices and corruption. 
Infringements of this kind are common with 
vendors as studies in Tanzania and Uganda 
showed similar violations [6,17]. In the study in 
Tanzania, 11 of the 30 shops studied lacked 
valid permit and none of the serving drug sellers 
met the qualification requirements for practising 
[6]. In  Uganda, only 39% of the drug shops were 
registered [21].  
 
In this study, all the drugs checked were duly 
registered, none had expired and there was 
almost a universal absence of injectable 
antimalarials. This contrasts with findings from 
similar studies in Tanzania where 63% stocked 
unregistered and 13% stocked expired 
antimalarials [6], and in Kenya where many 
unapproved and unregistered antimalarials were 
found and less than half of the recommended 
ones were registered [7]. Absence of 
unregistered or expired antimalarials in the 
observed shops was some evidence that the 
ongoing campaign against counterfeit drugs by 
NAFDAC was yielding result. Alternatively, could 
it be due to concealment of incriminating drugs 
by PMVs as has been reported in an earlier 
study [6]?   
 
Chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP), the former first and second 
line AMDs had the lion’s share of the market 
despite that they are no longer recommended 
except SP that is reserved for intermittent 
preventive treatment of malaria in pregnancy 
(IPTp) [9]. CQ and SP were replaced because of 
their reduced effectiveness occasioned by 
resistance of malaria parasite to them. Their 
dominance in drug shops means people are still 
exposed to inadequate treatment with 
consequences. Another worrisome finding was 
the wide availability of artemisinin 
monotherapies. The WHO recommended their 
withdrawal from the market because of evidence 
of resistance to them and the danger they pose 
to the ACTs [22]. Immediate withdrawal of these 
drugs and other non-artemisinin monotherapies, 
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Limitations of the study 
 
As noted earlier, the zone in Ikorodu LGA was 
purposively selected and might theoretically not 
be representative of the entire LGA. However, 
there is little doubt that it is similar in all respect 
to the other zones as they shared the same 
modus operandi being in the same LGA. 
NAPPMED members were not involved in the 
study. This limits generalization of the findings to 




This study shows poor compliance with 
regulatory guidelines and some significant 
differences of programmatic importance between 
the two study LGAs, even though both are rural. 
The ubiquitousness of PMVs can help to get 
ACTs to remote areas where formal heath care 
providers may not be present. However, given 
their poor compliance with some regulatory 
guidelines and the consequences of this for 
malaria treatment in the communities, there is a 
need for the authorized government agency to 
redouble its effort to enforce compliance and 
supervise their activities. Government should 
revise the list of antimalarials PMVs are 
permitted to sell to reflect the policy change and 
prevent the sale of ineffective antimalarials.  
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